NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease

Overview

Journal Neuroendocrinology

Publisher Karger

Specialties Endocrinology
Neurology

Date 2019 Jan 18

PMID 30654372

Citations 14

Authors

Anna Malczewska

Kjell Oberg

Lisa Bodei

Harry Aslanian

Anna Lewczuk

Pier Luigi Filosso

Monika Wojcik-Giertuga

Mateusz Rydel

Izabela Zielinska-Les

Agata Walter

Alejandro L Suarez

Agnieszka Kolasinska-Cwikla

Matteo Roffinella

Priya Jamidar

Dariusz Ziora

Damian Czyzewski

Beata Kos-Kudla

Jaroslaw Cwikla

Affiliations

Soon will be listed here.

Abstract

Background: There are no effective biomarkers for the management of bronchopulmonary carcinoids (BPC). We examined the utility of a neuroendocrine multigene transcript "liquid biopsy" (NETest) in BPC for diagnosis and monitoring of the disease status.

Aim: To independently validate the utility of the NETest in diagnosis and management of BPC in a multicenter, multinational, blinded study.

Material And Methods: The study cohorts assessed were BPC (n = 99), healthy controls (n = 102), other lung neoplasia (n = 101) including adenocarcinomas (ACC) (n = 41), squamous cell carcinomas (SCC) (n = 37), small-cell lung cancer (SCLC) (n = 16), large-cell neuroendocrine carcinoma (LCNEC) (n = 7), and idiopathic pulmonary fibrosis (IPF) (n = 50). BPC were histologically classified as typical (TC) (n = 62) and atypical carcinoids (AC) (n = 37). BPC disease status determination was based on imaging and RECIST 1.1. NETest diagnostic metrics and disease status accuracy were evaluated. The upper limit of normal (NETest) was 20. Twenty matched tissue-blood pairs were also evaluated. Data are means ± SD.

Results: NETest levels were significantly increased in BPC (45 ± 25) versus controls (9 ± 8; p < 0.0001). The area under the ROC curve was 0.96 ± 0.01. Accuracy, sensitivity, and specificity were: 92, 84, and 100%. NETest was also elevated in SCLC (42 ± 32) and LCNEC (28 ± 7). NETest accurately distinguished progressive (61 ± 26) from stable disease (35.5 ± 18; p < 0.0001). In BPC, NETest levels were elevated in metastatic disease irrespective of histology (AC: p < 0.02; TC: p = 0.0006). In nonendocrine lung cancers, ACC (18 ± 21) and SCC (12 ± 11) and benign disease (IPF) (18 ± 25) levels were significantly lower compared to BPC level (p < 0.001). Significant correlations were evident between paired tumor and blood samples for BPC (R: 0.83, p < 0.0001) and SCLC (R: 0.68) but not for SCC and ACC (R: 0.25-0.31).

Conclusions: Elevated -NETest levels are indicative of lung neuroendocrine neoplasia. NETest levels correlate with tumor tissue and imaging and accurately define clinical progression.

Citing Articles

BL-MOL-AR Project, Preliminary Results about Liquid Biopsy: Molecular Approach Experience and Research Activity in Oncological Settings.

Pancrazzi A, Bloise F, Moncada A, Perticucci R, Vecchietti S, Pompili F Glob Med Genet. 2023; 10(3):172-187.

PMID: 37457625 PMC: 10348843. DOI: 10.1055/s-0043-1771193.

Health Economic Evidence and Modeling Challenges for Liquid Biopsy Assays in Cancer Management: A Systematic Literature Review.

Fagery M, Khorshidi H, Wong S, Vu M, IJzerman M Pharmacoeconomics. 2023; 41(10):1229-1248.

PMID: 37351802 PMC: 10492680. DOI: 10.1007/s40273-023-01292-5.

Lung neuroendocrine tumors: A systematic literature review (Review).

Savu C, Melinte A, Diaconu C, Stiru O, Gherghiceanu F, Tudorica S Exp Ther Med. 2022; 23(2):176.

PMID: 35069857 PMC: 8764574. DOI: 10.3892/etm.2021.11099.

Liquid Biopsies: Applications for Cancer Diagnosis and Monitoring.

Martins I, Ribeiro I, Jorge J, Goncalves A, Sarmento-Ribeiro A, Melo J Genes (Basel). 2021; 12(3).

PMID: 33673461 PMC: 7997281. DOI: 10.3390/genes12030349.

The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future.

Liberini V, Huellner M, Grimaldi S, Finessi M, Thuillier P, Muni A Diagnostics (Basel). 2020; 10(12).

PMID: 33322819 PMC: 7763988. DOI: 10.3390/diagnostics10121083.

References

Filosso P, Kidd M, Roffinella M, Lewczuk A, Chung K, Kolasinska-Cwikla A . The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection and disease progression. Eur J Cardiothorac Surg. 2017; 53(3):631-639. DOI: 10.1093/ejcts/ezx386. View

Fernandez-Cuesta L, Peifer M, Lu X, Sun R, Ozretic L, Seidal D . Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nat Commun. 2014; 5:3518. PMC: 4132974. DOI: 10.1038/ncomms4518. View

Kadota K, Nitadori J, Rekhtman N, Jones D, Adusumilli P, Travis W . Reevaluation and reclassification of resected lung carcinomas originally diagnosed as squamous cell carcinoma using immunohistochemical analysis. Am J Surg Pathol. 2015; 39(9):1170-80. PMC: 4537681. DOI: 10.1097/PAS.0000000000000439. View

Caplin M, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E . Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015; 26(8):1604-20. DOI: 10.1093/annonc/mdv041. View

Lim S, Tan S, Lim W, Lim C . A merged lung cancer transcriptome dataset for clinical predictive modeling. Sci Data. 2018; 5:180136. PMC: 6057440. DOI: 10.1038/sdata.2018.136. View

Trisolini R, Valentini I, Tinelli C, Ferrari M, Guiducci G, Forti Parri S . DIPNECH: Association Between Histopathology and Clinical Presentation. Lung. 2016; 194(2):243-7. DOI: 10.1007/s00408-016-9854-7. View

Modlin I, Drozdov I, Kidd M . The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. PLoS One. 2013; 8(5):e63364. PMC: 3655166. DOI: 10.1371/journal.pone.0063364. View

Shi J, Li F, Luo M, Wei J, Liu X . Distinct Roles of Wnt/-Catenin Signaling in the Pathogenesis of Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis. Mediators Inflamm. 2017; 2017:3520581. PMC: 5447271. DOI: 10.1155/2017/3520581. View

Muscarella L, DAlessandro V, la Torre A, Copetti M, De Cata A, Parrella P . Gene expression of somatostatin receptor subtypes SSTR2a, SSTR3 and SSTR5 in peripheral blood of neuroendocrine lung cancer affected patients. Cell Oncol (Dordr). 2011; 34(5):435-41. DOI: 10.1007/s13402-011-0025-9. View

10.

Toffalorio F, Belloni E, Barberis M, Bucci G, Tizzoni L, Pruneri G . Gene expression profiling reveals GC and CEACAM1 as new tools in the diagnosis of lung carcinoids. Br J Cancer. 2014; 110(5):1244-9. PMC: 3950879. DOI: 10.1038/bjc.2014.41. View

11.

Cadioli A, Rossi G, Costantini M, Cavazza A, Migaldi M, Colby T . Lung cancer histologic and immunohistochemical heterogeneity in the era of molecular therapies: analysis of 172 consecutive surgically resected, entirely sampled pulmonary carcinomas. Am J Surg Pathol. 2014; 38(4):502-9. DOI: 10.1097/PAS.0000000000000154. View

12.

Kidd M, Modlin I, Mane S, Camp R, Eick G, Latich I . Utility of molecular genetic signatures in the delineation of gastric neoplasia. Cancer. 2006; 106(7):1480-8. DOI: 10.1002/cncr.21758. View

13.

Kidd M, Modlin I, Drozdov I, Aslanian H, Bodei L, Matar S . A liquid biopsy for bronchopulmonary/lung carcinoid diagnosis. Oncotarget. 2018; 9(6):7182-7196. PMC: 5805546. DOI: 10.18632/oncotarget.23820. View

14.

He P, Gu X, Wu Q, Lin Y, Gu Y, He J . Pulmonary carcinoid tumorlet without underlying lung disease: analysis of its relationship to fibrosis. J Thorac Dis. 2012; 4(6):655-8. PMC: 3506797. DOI: 10.3978/j.issn.2072-1439.2012.06.11. View

15.

Alvarez M, Subramaniam P, Tang L, Grunn A, Aburi M, Rieckhof G . A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. Nat Genet. 2018; 50(7):979-989. PMC: 6421579. DOI: 10.1038/s41588-018-0138-4. View

16.

Kidd M, Drozdov I, Modlin I . Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status. Endocr Relat Cancer. 2015; 22(4):561-75. DOI: 10.1530/ERC-15-0092. View

17.

Righi L, Volante M, Tavaglione V, Bille A, Daniele L, Angusti T . Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. Ann Oncol. 2009; 21(3):548-555. DOI: 10.1093/annonc/mdp334. View

18.

Tang H, Wang S, Xiao G, Schiller J, Papadimitrakopoulou V, Minna J . Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies. Ann Oncol. 2017; 28(4):733-740. PMC: 5834090. DOI: 10.1093/annonc/mdw683. View

19.

Bodei L, Kidd M, Modlin I, Prasad V, Severi S, Ambrosini V . Gene transcript analysis blood values correlate with ⁶⁸Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status. Eur J Nucl Med Mol Imaging. 2015; 42(9):1341-52. DOI: 10.1007/s00259-015-3075-9. View

20.

Hanley J, McNeil B . A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983; 148(3):839-43. DOI: 10.1148/radiology.148.3.6878708. View